Porustobart is under clinical development by Harbour BioMed (Guangzhou) and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Porustobart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HBM-4003 is under development for the treatment of advanced solid tumors including metastatic or unresectable metastatic melanoma, hepatocellular carcinoma and renal cell carcinoma, urothelial carcinoma, neuroendocrine cancer, neuroendocrine carcinoma and non-small cell lung cancer. The drug candidate is developed based on heavy chain only antibodies (HCAbs) transgenic mouse platform. It is administered by intravenous drip route and acts by targeting CTLA4.
Harbour BioMed (Guangzhou) overview
Harbour BioMed., a clinical-stage biopharmaceutical company that engaged in the provision of technology enabled healthcare services. The company is headquartered in China.
For a complete picture of Porustobart’s drug-specific PTSR and LoA scores, buy the report here.